Skip to main content
Top
Published in: Clinical Rheumatology 1/2017

01-01-2017 | Brief Report

Pre-injection of hyaluronic acid does not affect the systemic effects of intra-articular depot betamethasone injection at the knee joint

Authors: George Habib, Muhamad Khatib, Fahed Sakas, Suheil Artul, Haneen Jabaly-Habib

Published in: Clinical Rheumatology | Issue 1/2017

Login to get access

Abstract

Intra-articular injection (IAI) of both hyaluronic acid (HA) and depot-steroid preparations had the advantage of quick and prolonged favorable effects on pain relief among patients with symptomatic osteoarthritis of the knee (OAK). The effect of IAI of HA on the systemic effects of the intra-articular steroids had not been investigated. Non-selected patients attending the rheumatology clinic with symptomatic OAK who failed NSAIDS and physical therapy were offered an IAI of HA at the knee joint followed 20 min later by an IAI of 1 ml of Celestone Chronodose at the same joint (group 1). Morning serum levels of cortisol were obtained just prior to the IAI and 1, 2 and 8 days later. Demographic, clinical, and laboratory parameters were obtained also from all the patients. Age- and sex-matched group of patients from the same clinic were recruited as a control group (group 2). Mean baseline serum cortisol levels in group 1 was 381 ± 154 mmol/l vs. 376 ± 119 in group 2 (p = 0.954). Morning serum cortisol levels at day 1 and day 2 were 24 ± 6 and 22 ± 6 mmol/l, respectively, in group 1 patients vs. 27 ± 5.8 (p = 0.214) and 25 ± 5.6 mmol/l (p = 0.200), respectively, in group 2. These levels were significantly lower than baseline levels in each group. Morning serum cortisol levels at day 8 in group 1 and group 2 were 349 ± 128 and 314 ± 99 mmol/l, respectively (p = 0.419). Pre-injection of HA at the knee joint did not affect the systemic effect on the hypothalamic-pituitary-adrenal axis of IAI of Celestone Chronodose.
Literature
1.
go back to reference Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2005) Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2, CD005328 Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2005) Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2, CD005328
2.
3.
go back to reference Hiskisson EC, Donnelly S (1999) Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford) 38:602–607CrossRef Hiskisson EC, Donnelly S (1999) Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford) 38:602–607CrossRef
4.
go back to reference Bannuru RR, Natov NS, Dasi CH, McAlindon TE (2011) Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis- meta-analysis. Osteoarthr Cartil 611–19 Bannuru RR, Natov NS, Dasi CH, McAlindon TE (2011) Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis- meta-analysis. Osteoarthr Cartil 611–19
5.
go back to reference Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R (2006) The safety and efficacy of intraarticular hyaluroninan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. Rheumatol Int 26:314–319CrossRefPubMed Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R (2006) The safety and efficacy of intraarticular hyaluroninan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. Rheumatol Int 26:314–319CrossRefPubMed
6.
go back to reference Necas J, Bartosikova L, Brauner P, Kolar J (2008) Hyaluronic acid (Hyaluronan): a review. Vet Med 53:397–411 Necas J, Bartosikova L, Brauner P, Kolar J (2008) Hyaluronic acid (Hyaluronan): a review. Vet Med 53:397–411
7.
8.
go back to reference Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagn Ther Crit Committee Am Rheum Assoc Arthritis Rheum 29:1039–1049 Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagn Ther Crit Committee Am Rheum Assoc Arthritis Rheum 29:1039–1049
9.
go back to reference Bertouch JV, Sallustio BC, Meffin PJ, Brooks PM (1983) A comparison of plasma methylprednisolone concentration following intr-articular injection in patients with rheumatoid arthritis and osteoarthritis. Aus NZ JM 13:583–586CrossRef Bertouch JV, Sallustio BC, Meffin PJ, Brooks PM (1983) A comparison of plasma methylprednisolone concentration following intr-articular injection in patients with rheumatoid arthritis and osteoarthritis. Aus NZ JM 13:583–586CrossRef
10.
go back to reference Armstrong RD, English J, Gibson T, Chakraborty J, Marks V (1981) Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate. ARD 40:571–574PubMedPubMedCentral Armstrong RD, English J, Gibson T, Chakraborty J, Marks V (1981) Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate. ARD 40:571–574PubMedPubMedCentral
11.
go back to reference Habib G, Safia A (2009) The effects of intra-articualr injection of betamethasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee. Clin Rheum 28:85–87CrossRef Habib G, Safia A (2009) The effects of intra-articualr injection of betamethasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee. Clin Rheum 28:85–87CrossRef
12.
go back to reference Smith MM, Ghosh P (1987) The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronic acid in the extracellular environment. Rheumatol Int 7:113–122CrossRefPubMed Smith MM, Ghosh P (1987) The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronic acid in the extracellular environment. Rheumatol Int 7:113–122CrossRefPubMed
13.
go back to reference Mo Y, Liu X, Hong H (2013) Pathological changes in synovium after sodium hyaluronate treatment of knee osteoarthritis. Pract Clin Med 5 Mo Y, Liu X, Hong H (2013) Pathological changes in synovium after sodium hyaluronate treatment of knee osteoarthritis. Pract Clin Med 5
14.
go back to reference Henrotin Y, Chevalier X, Deberg M et al (2013) Early decrease of serum biomarkers of type II collagen degradation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study. J Orthop Res 901–7 Henrotin Y, Chevalier X, Deberg M et al (2013) Early decrease of serum biomarkers of type II collagen degradation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study. J Orthop Res 901–7
Metadata
Title
Pre-injection of hyaluronic acid does not affect the systemic effects of intra-articular depot betamethasone injection at the knee joint
Authors
George Habib
Muhamad Khatib
Fahed Sakas
Suheil Artul
Haneen Jabaly-Habib
Publication date
01-01-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 1/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3352-4

Other articles of this Issue 1/2017

Clinical Rheumatology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine